Trials / Completed
CompletedNCT07079644
Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
Real World Outcomes of Nivolumab + Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 678 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab + Relatlimab | As per product label |
| BIOLOGICAL | Nivolumab + Ipilimumab | As per product label |
| BIOLOGICAL | Immunotherapy monotherapy | As per product label |
| DRUG | BRAF/MEK inhibitors | As per product label |
Timeline
- Start date
- 2024-11-29
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2025-07-23
- Last updated
- 2025-07-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07079644. Inclusion in this directory is not an endorsement.